CURE® Magazine Releases Its Rare Cancers Specialty Issue
Aug. 02, 2018
CRANBURY, N.J.--(BUSINESS WIRE)--Aug 2, 2018--CURE® magazine, the nation’s leading consumer digital and print media enterprise focused on patients with cancer, published its most recent Rare Cancers issue, announced Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of CURE® magazine.
In making the announcement, Michael J. Hennessy, Jr said, “Our Rare Cancers issue hits close to home, as we are the leading resource for cancer updates, research and education within the cancer community. It is our mission to continue our efforts in providing the most up-to-date research and studies to cancer patients, survivors and their caregivers.”
Although the oncology field continues to advance in many ways, studying a rare cancer — defined by the American Cancer Society as fewer than six cases per 100,000 people each year — presents a challenge due to the rarity of these diseases.
In this issue, CURE® focuses its cover story, Advances and Combinations Raise Sights on Uveal Melanoma, on the clinical trials that seek to discover new ways to attack cancer of the eye, limit metastasis and prevent recurrence of the disease. Two patients share their very different journeys with uveal melanoma — one woman developing metastasis to her liver and brain — and how they are doing today.
Also in this issue, CURE® features:Turning the Tide. Innovations in drug development, surgery, radiation and clinical trials have investigators hard at work in glioblastoma. Waldenstrom Macroglobulinemia: The Discovery and What Lies Ahead. This incurable rare cancer of the lymphatic system has seen improvements, but what is the best strategy for treating patients with the disease? Training Through Treatments: Pro Runner Doesn’t Let Rare Cancer Slow Her Down. After receiving a diagnosis of adenoid cystic carcinoma, Gabriele Grunewald wanted to help others and founded Brave Like Gabe.
In addition, the magazine offers news and updates within the rare cancer space, from a Food and Drug approval in thyroid cancer to clinical trials in pediatric cancers and new targeted therapies for a mantle cell lymphoma prognosis.
To read more from the Rare Cancers Special Issue, visit curetoday.com.
About CURE Media Group
CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry-leading website, CUREtoday.com; innovative video programs, such as CURE Connections ®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers. CURE Media Group is part of the Cranbury, New Jersey-based MJH Associates Inc. family of businesses, which includes the acclaimed OncLive ® ( http://www.onclive.com ) platform of resources for the practicing oncologist. For more information, visit http://www.curetoday.com and http://www.mjhassoc.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005559/en/
CONTACT: CURE Media Group
Theresa Burek, 609-325-4811
Alexandra Ventura, 609-716-7777, ext. 121
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS ONCOLOGY OTHER HEALTH COMMUNICATIONS RESEARCH OTHER SCIENCE PUBLISHING SCIENCE
SOURCE: CURE Media Group
Copyright Business Wire 2018.
PUB: 08/02/2018 10:45 AM/DISC: 08/02/2018 10:45 AM